score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved	Preclinical	Inferential	Copy Number	ERBB2	Amplification				0.0	0.0		Putatively Actionable	Ado-Trastuzumab Emtansine	ER signaling inhibition	Hormone therapy	HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy.	Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf	Putatively Actionable	Radiation therapy	Radiation	Radiation therapy	Breast cancer cells with HER2 amplification demonstrate radiation resistance, which can be reversed with trastuzumab.	Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Molecular cancer therapeutics. 2003; 2(11):1113-20. 	https://mct.aacrjournals.org/content/2/11/1113.long	Putatively Actionable	0.0	Overexpression and gene amplification of ErbB2 (HER2/neu) is an adverse prognostic indicator associated with aggressive histopathologic parameters and correlated with decreased disease-free survival and overall survival (OS) in breast cancer (BC).	F Revillion, J Bonneterre, JP Peyrat: ERBB2 oncogene in human breast cancer and its clinical significance Eur J Cancer 34: 791	https://doi.org/10.1016/S0959-8049(97)10157-5	0				ERBB2 Amplification		KIRP-4A-A93Y	TCGA-4A-A93Y-01	
Putatively Actionable	Preclinical		Preclinical	Copy Number	AURKA	Amplification				0.0	0.0		Putatively Actionable	Danusertib	Aurora kinase inhibition	Targeted therapy	Neuroendocrine prostate cancer (NEPC) cell lines shows enhanced sensitivity to pan-Aurora kinase inhibitor therapy, specifically to PHA-739358 (Danusertib).	Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1(6):487-95.	https://doi.org/10.1158/2159-8290.CD-11-0130								Putatively Actionable	0.0	Downmodulation of TPX2 and AURKA in the presence of 20q copy gain was shown to tumor growth	"Sillars-Hardebol, Anke H., et al. ""TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression."" Gut 61.11 (2012): 1568-1575."	https://doi.org/10.1136/gutjnl-2011-301153	0				AURKA Amplification		KIRP-4A-A93Y	TCGA-4A-A93Y-01	
Putatively Actionable			Preclinical	Copy Number	TPX2	Amplification				0.0	0.0																Putatively Actionable	0.0	Downmodulation of TPX2 and AURKA in the presence of 20q copy gain was shown to tumor growth	"Sillars-Hardebol, Anke H., et al. ""TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression."" Gut 61.11 (2012): 1568-1575."	https://doi.org/10.1136/gutjnl-2011-301153	0				TPX2 Amplification		KIRP-4A-A93Y	TCGA-4A-A93Y-01	
Biologically Relevant				Copy Number	ASXL1	Amplification				0.0	0.0																					0				ASXL1 Amplification		KIRP-4A-A93Y	TCGA-4A-A93Y-01	
Biologically Relevant				Copy Number	COL1A1	Amplification				0.0	0.0																					0				COL1A1 Amplification		KIRP-4A-A93Y	TCGA-4A-A93Y-01	
Biologically Relevant				Copy Number	CDK12	Amplification				0.0	0.0																					0				CDK12 Amplification		KIRP-4A-A93Y	TCGA-4A-A93Y-01	
Biologically Relevant				Copy Number	FLCN	Amplification				0.0	0.0																					0				FLCN Amplification		KIRP-4A-A93Y	TCGA-4A-A93Y-01	
Biologically Relevant				Copy Number	BRCA1	Amplification				0.0	0.0																					0				BRCA1 Amplification		KIRP-4A-A93Y	TCGA-4A-A93Y-01	
Biologically Relevant				Copy Number	BRIP1	Amplification				0.0	0.0																					0				BRIP1 Amplification		KIRP-4A-A93Y	TCGA-4A-A93Y-01	
Biologically Relevant				Copy Number	NF1	Amplification				0.0	0.0																					0				NF1 Amplification		KIRP-4A-A93Y	TCGA-4A-A93Y-01	
Biologically Relevant				Copy Number	RAD51C	Amplification				0.0	0.0																					0				RAD51C Amplification		KIRP-4A-A93Y	TCGA-4A-A93Y-01	
Biologically Relevant				Copy Number	RAD51D	Amplification				0.0	0.0																					0				RAD51D Amplification		KIRP-4A-A93Y	TCGA-4A-A93Y-01	
Biologically Relevant				Microsatellite Stability	Supporting variants		RNF43 Amplification, MSH3 p.-59fs (Frameshift), MSH3 p.A61fs (Frameshift), MSH3 p.61_62insAPPAPPAPP (Insertion), MSH3 p.61_62insPP (Insertion), MSH3 p.E523K (Splice Site)																									0				Supporting variants: RNF43 Amplification, MSH3 p.-59fs (Frameshift), MSH3 p.A61fs (Frameshift), MSH3 p.61_62insAPPAPPAPP (Insertion), MSH3 p.61_62insPP (Insertion), MSH3 p.E523K (Splice Site)		KIRP-4A-A93Y		
Biologically Relevant				Mutational Signature	COSMIC Signature 8	version 2	0.225																									0				COSMIC Signature (version 2) 8 (22%)		KIRP-4A-A93Y		
Biologically Relevant				Mutational Signature	COSMIC Signature 16	version 2	0.431																									0				COSMIC Signature (version 2) 16 (43%)		KIRP-4A-A93Y		
